Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

From the plant

CBGMCannabigerol monomethyl ether

Methyl ether of CBG described in 1968; a single pharmacological study, on rat neurons.

Unscheduled
Level of detail

C₂₂H₃₄O₂

CAS 29106-17-0

Family
PhytocannabinoidMinor
Origin
Origin not established
Molar mass
330.50 g/mol

Updated on

In plain terms

CBGM is a variant of CBG in which one of the two hydroxyl groups carries a methyl. It was described in hemp in 1968, without anyone knowing how the plant forms it. The only study of its activity, on cultured rat neurons, shows that it dampened the response to capsaicin; no human data exist.

Receptors and activity

Target network

TRPV1ModulatorReduction of the calcium entry evoked by capsaicin in sensitised rat dorsal root ganglion neurons (0.001 to 100 µM); no IC50 published, direct mechanism not established (Anand et al. 2025)
  • Binds or modulates

The lower the cited value, the closer the target sits to CBGM: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of CBGM.

Brain, side view
Body, front view
Blood

TRPV1TRPV1 found in 7 regions of the body

  1. Sensory gangliapresentExpressed in dorsal root ganglia1
  2. Spinal cordpresentNerve fibres in the spinal dorsal horn2
  3. CortexpresentParietal cortex neurons (layers 3 and 5)3
  4. SkinpresentWidely distributed in the skin4
  5. Blood vesselspresentPresent on dermal blood vessels4
  6. BonepresentPresent on osteoclasts5
  7. LiverpresentRNA enriched in the liver6

Map sources

  1. Cortright DN et al. The tissue distribution and functional characterization of human VR1. Biochem Biophys Res Commun, 2001 (new tab)
  2. Facer P et al. Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy. BMC Neurol, 2007 (new tab)
  3. Mezey E et al. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci U S A, 2000 (new tab)
  4. Ständer S et al. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol, 2004 (new tab)
  5. Rossi F et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone, 2009 (new tab)
  6. Human Protein Atlas. TRPV1 tissue expression (RNA consensus) (new tab)

Cited values

  1. TRPV1Modulatorno measured value cited

    Reduction of the calcium entry evoked by capsaicin in sensitised rat dorsal root ganglion neurons (0.001 to 100 µM); no IC50 published, direct mechanism not established (Anand et al. 2025)

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Measured effects

Not characterised. No placebo-controlled human trial has measured the effects of CBGM, so no level is shown.

Levels computed from placebo-controlled human trials: difference from placebo on 100, at the dose and route stated. Read the method

Pharmacology

Cannabigerol monomethyl ether (CBGM) is CBG with a methyl on one of its two phenolic hydroxyls. Described in 1968 by Yamauchi et al. as a « new component of hemp », it is linked by Radwan et al. (2021) to a 1966 isolation from Japanese hemp (Obata and Ishikawa); its acid form, CBGAM, was described in 1970. Its origin in the plant is not established, as no methylating enzyme has been described. No CB1 or CB2 affinity has been published. The only pharmacological data come from a 2025 study on sensitised cultured rat sensory neurons: alongside nine other minor cannabinoids, tested from 0.001 to 100 µM, CBGM reduced capsaicin-evoked calcium influx, which the authors attribute to inhibition of TRPV1 signalling, without itself triggering calcium influx (Anand et al. 2025). No pharmacokinetic, metabolism or toxicology data and no human data exist.

Key sources.

History

Source
Cannabis sativa L.: isolated from a hemp extract (Radwan et al. 2021); Linciano et al. (2020) list it among the methyl ethers of the plant already isolated and characterised. Origin not established: no methylating enzyme has been described. Its acid form, CBGAM, was described in hemp in 1970 (Shoyama et al.).

Biosynthetic pathway

Origin not established. The plant forms cannabigerolic acid (CBGA) from olivetolic acid and geranyl pyrophosphate (Luo et al. 2019); CBGM is CBG with one phenolic hydroxyl methylated, and its acid form, CBGAM, has been known since 1970 (Shoyama et al.). No responsible methyltransferase has been described in the sources consulted.

Classification

Family, origin and source verification

Family

Phytocannabinoid › Minor

Presence in the plant

Present in the plant; origin not established

Chemistry

Type CBG · C5 side chain · neutral form

Verification

Every fact on this entry was checked against its primary sources on 20 October 2026.

Wikipedia (English)

No dedicated article.

References

  1. Yamauchi T., Shoyama Y., Matsuo Y., Nishioka I. 1968, Chem Pharm Bull 16:1164-1165: cannabigerol monomethyl ether, a new constituent of hemp (new tab)PMID 5706840
  2. Obata Y., Ishikawa Y. 1966, Agric Biol Chem 30:619-620: constituents of hemp, III, isolation of a Gibbs-positive compound from Japanese hemp (cited by Radwan 2021 for the isolation of CBGM) (new tab)DOI 10.1271/bbb1961.30.619
  3. Shoyama Y., Yamauchi T., Nishioka I. 1970, Chem Pharm Bull 18:1327-1332: Cannabis V, cannabigerolic acid monomethyl ether and cannabinolic acid (new tab)DOI 10.1248/cpb.18.1327
  4. Radwan M.M. et al. 2021, Molecules 26:2774: inventory of cannabinoids, CBG-type subclass (new tab)PMID 34066753
  5. Linciano P. et al. 2020, Sci Rep: CBGM and CBDM, methyl ethers already isolated and characterised (new tab)PMID 33328530
  6. Anand U., Anand P., Sodergren M.H. 2025, J Pain Res: effects of ten minor cannabinoids on an in vitro model of neuronal hypersensitivity (new tab)PMID 41322279
  7. Luo X. et al. 2019, Nature 567:123-126: complete biosynthesis of CBGA in yeast (new tab)PMID 30814733
  8. PubChem CID 13864080: cannabigerol monomethyl ether, (2E) (identifiers) (new tab)
  9. ANSM, consolidated list of substances classified as narcotics, updated 26/06/2026 (new tab)

Identifiers

Names

Common name
Cannabigerol monomethyl ether
IUPAC name
2-[(2E)-3,7-dimethylocta-2,6-dienyl]-3-methoxy-5-pentylphenol
Other names
CBGM

Identifiers

Formula
C₂₂H₃₄O₂
CAS
29106-17-0
PubChem CID
13864080(new tab)
InChIKey
KASVLYINZPAMNS-QGOAFFKASA-N
SMILES
CCCCCC1=CC(=C(C(=C1)OC)C/C=C(\C)/CCC=C(C)C)O

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.